Clinical trial NCT04295915: Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates
Official title: Clinical Performance and Reproducibility of the Accelerate PhenoTest™ BC Kit Using the Accelerate Pheno™ System With New Antibiotic Wave I Updates for Antimicrobial Susceptibility Testing of Positive Blood Culture Specimens
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bacteremia
Keywords: Positive blood culture
Lead sponsor: Accelerate Diagnostics, Inc.
Sponsor class: INDUSTRY
First posted: 2020-03-05
Enrollment: 731
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Clinical or contrived (seeded bacterial isolate) specimens that are indicated as positive by blood culture monitoring systems utilized by clinical microbiology laboratories.

Brief summary: This is a performance and reproducibility study to validate new or updated antimicrobials on the Accelerate PhenoTest™ BC kit. The data from this study will be used to support the submission to the FDA for clearance in the US and for global registrations of the device intended for in vitro diagnostic use.

Detailed description: This clinical study entitled "Clinical Performance and Reproducibility of the Accelerate PhenoTest™ BC Kit Using the Accelerate Pheno™ System with New Antibiotic Wave I Updates for Antimicrobial Susceptibility Testing of Positive Blood Culture Specimens" is designed to demonstrate the clinical performance and reproducibility of the new or updated antimicrobials on the Accelerate PhenoTest™ BC kit, which was previously FDA-cleared in February 2017.

Clinical performance and reproducibility evaluations will be conducted at a minimum of three sites to determine the clinical performance of the new or updated antimicrobials from a combination of fresh (de-identified, remnant specimens) and contrived positive blood culture samples, to include at least 375 total specimens.

The study sites selected will have expertise in blood culture diagnostics and will be able to conduct the study in accordance with this protocol and Good Clinical Practices (GCP). Additionally, prior to study initiation, each site will have approval from the local Institutional Review Board (IRB).

It is anticipated that the data from this study will be used to support the submission to the FDA for clearance in the US and for global registrations of the device intended for in vitro diagnostic use.

Eligibility criteria: Inclusion Criteria:

* Blood culture positivity is ≤ 8 hours prior to initiation of testing with the Accelerate Pheno™ system
* Positive blood culture sample containing gram-negative rods according to Gram stain results
* For fresh specimens, de-identified, remnant positive blood culture specimens from patients for which Standard of Care (SOC) testing has been initiated and the remaining samples would otherwise be discarded
* A minimum sample volume of 2.0 mL
* Seeded blood culture specimens derived from archived bacterial

Exclusion Criteria:

* Blood culture positivity is \> 8 hours prior to initiation of testing with the Accelerate Pheno™ system
* Insufficient (less than 2.0 mL) remnant sample volume
* From a patient that has already been enrolled in the study
* Fresh samples from Mycobacterial-type blood culture media (BACTEC™ Myco/F Lytic, BacT/ALERT® MP Bottle, VersaTREK® Myco) or charcoal-containing media
* Seeded specimens that appear mixed (by Gram stain or purity plating) after bottle culture positivity

Primary outcomes:
measure: Essential and categorical agreement with Clinical and Laboratory Standards Institute (CLSI) broth microdilution reference method
timeFrame: Approximately 4 months
Secondary outcomes:
measure: Essential agreement of MICs compared to the modal MIC values obtained for intra- and inter-laboratory results
timeFrame: Approximately 2 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Accelerate Diagnostics
state: Arizona
city: Hershey
country: United States
facility: Penn State-Hershey Medical Center
state: Pennsylvania
city: Lewisville
country: United States
facility: Quest/med fusion
state: Texas
Study officials:
affiliation: Accelerate Diagnostics, Inc.
name: Shelley Campeau
role: STUDY_DIRECTOR
References: